$BCYC

Perry Jennifer Scott sold $6K of BCYC

Perry Jennifer Scott (Chief Operating Officer) sold 1,412 shares of BICYCLE THERAPEUTICS PLC (BCYC) at an average of $4.29 ($4.27–$4.34) across 3 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Perry Jennifer Scott
Published Jul 7, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BCYC
Neutral
high confidence
Mentioned
$BCYC
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCYCNeutralLow
01

Why it matters

Insider sales can influence sentiment, but 10b5-1 pre-arranged selling and the modest transaction value reduce the likelihood of a durable price reaction.

02

Market read

Traders may note the disclosure for sentiment monitoring, but it does not introduce new fundamentals or a time-critical corporate event.

03

What to watch

The article provides only the sale details; without concurrent buys, guidance, trial updates, or financing news, the trading signal is weak.

Relevance 2/10Novelty 3/10Timing: Form 4 filed July 7 after sales executed July 2–6

Background

The article is a SEC Form 4 insider transaction disclosure for Bicycle Therapeutics PLC (BCYC).

Company-level read

Ticker impact

$BCYCNeutralHigh confidence
Context

Bicycle Therapeutics COO Perry Jennifer Scott sold $6,054 of BCYC shares in open-market trades under a 10b5-1 plan (Form 4 filed July 7).

Expected impact

Low near-term impact; any effect is likely short-lived unless paired with other new company-specific catalysts.

Evidence & confidence

The filing is an insider transaction (S sale) with a pre-arranged 10b5-1 plan and small dollar value, providing disclosure but not a new operating or financial datapoint.

Market effects

Minimal—single-company insider sale with no sector-wide regulatory/clinical/financial update.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity needs rather than negative expectations; traders may discount it.

Key entities

  • Bicycle Therapeutics PLC

    Subject of the Form 4 insider transaction disclosure.

  • Perry Jennifer Scott

    Chief Operating Officer who sold shares in open-market transactions.

  • 10b5-1 plan

    Pre-arranged plan indicating the trades were scheduled in advance.

Related articles

$BCYCMed

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2026 results and business updates. It cited AACR/ASCO data for nuzefatide in EphA2-expressing cancers, including Phase 2 recurrent pancreatic cancer with first patient dosed in April 2026. Cash was $510.1M at June 30, 2026, funding into 2030. Duravelo-2 interim Week 27 ORR was 65% (17/26).

$BCYCMed

BICYCLE THERAPEUTICS PLC (BCYC): Results of Operations and Financial Condition

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621593d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology thera